Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tandem Diabetes Care, Inc. (NASDAQ: TNDM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tandem Diabetes Care is a global insulin delivery and diabetes technology company whose common stock is registered under Section 12(b) of the Exchange Act and listed on the NASDAQ Global Market under the symbol TNDM.
Through this page, users can review current reports on Form 8-K that document material events such as quarterly earnings announcements, regulatory clearances, and board of director changes. Recent 8-K filings referenced by the company include reports on financial results for quarters ended during 2025 and the appointment of a new independent director to the board, along with related committee assignments and compensation details. Other 8-K filings describe FDA 510(k) clearance for the SteadiSet infusion set and similar operational milestones.
In addition to 8-Ks, Tandem Diabetes Care files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed information on its insulin delivery systems, financial condition, risk factors, and business strategy. These filings are important for understanding how the company’s pump portfolio, infusion sets, mobile applications, and cloud-based platforms contribute to its overall operations and financial results.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify information on revenue drivers, regulatory developments, and governance matters. The platform also surfaces insider transaction reports on Form 4 when available, allowing investors to monitor share transactions by directors and officers. Real-time updates from the SEC’s EDGAR system ensure that new Tandem Diabetes Care filings appear promptly, while AI-generated explanations make complex regulatory language more accessible.
Tandem Diabetes Care executive Mark David Novara reported equity award activity involving restricted stock units (RSUs) and common shares. On February 17, he exercised 77 RSUs, converting them into 77 shares of common stock at no exercise price under the company’s long-term incentive plan.
Of the resulting shares, 62 common shares were withheld by Tandem Diabetes Care to cover tax withholding obligations upon vesting of the RSUs, as disclosed in the footnotes, and no shares were sold on the open market. After these transactions, Novara directly held 35,971 shares of common stock and 380 RSUs.
Tandem Diabetes Care president and CEO John F. Sheridan reported equity compensation activity tied to restricted stock units (RSUs). On February 17, he acquired common shares through the exercise or conversion of RSUs, while a portion of the vested shares was withheld to cover tax obligations.
The filing shows tax-withholding dispositions of 1,963 and 2,400 common shares at $18.95 per share, with a footnote clarifying these were shares retained by the company to satisfy taxes and that no shares were sold on the open market.
Tandem Diabetes Care EVP & CFO Leigh Vosseller reported the vesting and exercise of restricted stock units into common stock, along with related tax withholding transactions. On February 17, 2026, 1,503 and 1,495 restricted stock units were converted into common shares at $0.00 per share. To cover tax obligations, 619 and 616 common shares were withheld at $18.95 per share, and a footnote states that no shares were sold. Following these transactions, Vosseller held 39,411 common shares directly and 25,580 common shares indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care executive vice president and chief legal officer Shannon Marie Hansen reported equity award activity involving restricted stock units and common stock. On February 17, 2026, several RSU awards vested and were converted into common shares at no exercise price.
Across these transactions, Hansen acquired common stock through derivative exercises coded "M" and had portions of the newly delivered shares withheld, coded "F", to cover tax obligations at $18.95 per share, with a footnote stating no shares were sold in the market. Following these movements, she directly held 23,276 shares of common stock. An additional 1,935 shares were reported as held indirectly through the Shannon M. Hansen Trust, where she serves as trustee.
Tandem Diabetes Care files its annual report describing a global insulin-delivery business built around its X2 and Tandem Mobi pumps, both using Control‑IQ+ automated insulin delivery technology. The company serves nearly 500,000 people with insulin‑dependent diabetes across more than 25 countries and is expanding from type 1 into intensive‑insulin type 2 therapy.
Tandem highlights a shift to a multi‑channel reimbursement model in the U.S., adding pharmacy benefits alongside traditional durable medical equipment coverage. The filing outlines manufacturing in San Diego with key third‑party suppliers, a growing international footprint with more direct sales, and a sizeable patent portfolio. It also details significant risks, including a $1.3 billion accumulated deficit, dependence on pump sales, competitive pressure from large diabetes technology companies and GLP‑1 drug uptake, reimbursement and regulatory uncertainty, cybersecurity and data‑privacy obligations, and the need to service Convertible Senior Notes due 2029.
Tandem Diabetes Care reported record fourth-quarter 2025 results, with worldwide sales of $290.4 million and pump shipments of 38,000. GAAP gross margin reached a record 58%, generating operating income of $8.3 million, while net loss for the quarter was a modest $0.6 million.
For full-year 2025, worldwide sales rose to $1.015 billion, up 12% on a non-GAAP basis, with more than 126,000 pumps shipped and gross margin expanding to 54%. However, GAAP net loss widened to $204.7 million and adjusted EBITDA was negative $46.1 million, pressured by a $75.2 million acquired in-process R&D charge and other costs.
For 2026, the company guides sales to $1.065–$1.085 billion, gross margin of 56–57%, and adjusted EBITDA margin of 5–6%. Guidance reflects a U.S. transition to a pay-as-you-go pharmacy model and direct international operations, including an estimated $70–$80 million sales headwind from the new U.S. model.
ArrowMark Colorado Holdings, LLC filed an amended Schedule 13G to report its passive ownership in DIABETES CARE INC common stock. As of the event date of 12/31/2025, ArrowMark reported beneficial ownership of 2,889,691 shares, representing 4.26% of the outstanding common stock.
ArrowMark, a Delaware entity, disclosed sole voting and dispositive power over all of these shares and no shared power with other parties. It certified that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported routine equity compensation activity. On 01/15/2026, 3,636 restricted stock units were converted into an equal number of common shares at an exercise price of $0. Of these, 2,118 shares were withheld by Tandem Diabetes Care to satisfy tax withholding obligations at $21.07 per share, and no shares were sold into the market. Following these transactions, Kyrillos directly held 24,062 shares of common stock and 21,817 restricted stock units, all under the company’s 2023 Long-Term Incentive Plan.
Tandem Diabetes Care Inc. executive vice president and chief commercial officer Mark D. Novara reported equity activity involving company stock. On 12/15/2025, 7,415 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units granted under the 2023 Long-Term Incentive Plan. To cover tax withholding on this vesting, 3,843 shares were withheld by the company at a price of $22.11 per share, and no shares were sold into the market.
After these transactions, Novara directly beneficially owned 35,956 shares of Tandem Diabetes Care common stock and 29,658 restricted stock units, each representing a contingent right to receive one share of common stock or cash, in accordance with the plan’s terms.
Tandem Diabetes Care Inc. reported an insider equity transaction by its Chief Technology Officer, Rick A. Carpenter. On 12/15/2025, 406 restricted stock units (RSUs) granted on 12/15/2021 under the company’s 2013 Stock Incentive Plan were converted into common stock at an exercise price of $0.
To cover tax withholding on the RSU vesting, the company withheld 207 shares at a price of $22.11 per share, and no shares were sold on the open market. After these transactions, Carpenter directly holds 24,252 shares of Tandem Diabetes Care common stock.